Studies in the Area of Chronic Obstructive Pulmonary Disease Reported from GlaxoSmithKline plc (Claims-Based Risk Model for First Severe COPD…

Insurance Weekly News

Studies in the Area of Chronic Obstructive Pulmonary Disease Reported from GlaxoSmithKline plc (Claims-Based Risk Model for First Severe COPD Exacerbation)

By a News Reporter-Staff News Editor at Insurance Weekly News -- Investigators publish new report on Lung Diseases and Conditions - Chronic Obstructive Pulmonary Disease. According to news reporting originating from Research Triangle Park, North Carolina, by VerticalNews correspondents, research stated, "To develop and validate a predictive model for first severe chronic obstructive pulmonary disease (COPD) exacerbation using health insurance claims data and to validate the risk measure of controller medication to total COPD treatment (controller and rescue) ratio (CTR). A predictive model was developed and validated in 2 managed care databases: Truven Health MarketScan database and Reliant Medical Group database."

Our news editors obtained a quote from the research from GlaxoSmithKline plc, "This secondary analysis assessed risk factors, including CTR, during the baseline period (Year 1) to predict risk of severe exacerbation in the at-risk period (Year 2). Patients with COPD who were 40 years or older and who had at least 1 COPD medication dispensed during the year following COPD diagnosis were included. Subjects with severe exacerbations in the baseline year were excluded. Risk factors in the baseline period were included as potential predictors in multivariate analysis. Performance was evaluated using C-statistics. The analysis included 223,824 patients. The greatest risk factors for first severe exacerbation were advanced age, chronic oxygen therapy usage, COPD diagnosis type, dispensing of 4 or more canisters of rescue medication, and having 2 or more moderate exacerbations. A CTR of 0.3 or greater was associated with a 14% lower risk of severe exacerbation. The model performed well with C-statistics, ranging from 0.711 to 0.714. This claims-based risk model can predict the likelihood of first severe COPD exacerbation. The CTR could also potentially be used to target populations at greatest risk for severe exacerbations."

According to the news editors, the research concluded: "This could be relevant for providers and payers in approaches to prevent severe exacerbations and reduce costs."

For more information on this research see: Claims-Based Risk Model for First Severe COPD Exacerbation. American Journal of Managed Care, 2018;24(2):E45-E53,116-117. American Journal of Managed Care can be contacted at: Managed Care & Healthcare Communications Llc, 666 Plainsboro Rd, Ste 300, Plainsboro, NJ 08536, USA.

The news editors report that additional information may be obtained by contacting R.H. Stanford, GlaxoSmithKline, Res Triangle Pk, NC 27709, United States. Additional authors for this research include A. Nag, D.W. Mapel, T.A. Lee, R. Rosiello, M. Schatz, F. Vekeman, M. Gauthier-Loiselle, J.F.P. Merrigan and M.S. Duh.

Keywords for this news article include: Research Triangle Park, North Carolina, United States, North and Central America, Chronic Obstructive Pulmonary Disease, Lung Diseases and Conditions, Pharmaceutical Companies, GlaxoSmithKline plc, Risk and Prevention, Health and Medicine, Business, GlaxoSmithKline plc.